KLK4 and hereditary angioedema: Lanadelumab is a plasma kallikrein inhibitor that is approved as 1st line therapy in Canada for long term prophylaxis of HAE attacks.<h4>Objective</h4>To describe our clinical findings from a case series of adult patients with HAE type 1/2 who have been initiated on lanadelumab.<h4>Methods</h4>A chart review of HAE type 1/2 patients at three academic centers in Canada was undertaken with demographic and clinical data extracted.